Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for people with untreated PD-L1-positive metastatic non-small-cell lung cancer.
Following on from information provided to NICE by the company in August 2022, the appraisal of Durvalumab for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations and high PD-L1 expression [ID3762] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA
ID number 3762

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 August 2023 Discontinued. Following on from information provided to NICE by the company in August 2022, the appraisal of Durvalumab for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations and high PD-L1 expression [ID3762] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
05 August 2022 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations and high PD-L1 expression. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
21 October 2020 - 18 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 March 2020 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual